Mounjaro jab sites: where to inject, how to rotate, and what the evidence says

What the licensed guidance actually says about injection sites

The Mounjaro SmPC (the authoritative product document reviewed by the MHRA before licensing) lists the abdomen, front of the thigh and outer upper arm as the three approved subcutaneous injection sites. All three deliver tirzepatide into the fatty tissue just beneath the skin, where it is absorbed gradually into the bloodstream. The NHS medicines page for tirzepatide echoes this, noting that the injection should go into the fatty area of whichever site you choose.

Subcutaneous absorption is broadly comparable across all three locations for most people, though individual factors like body composition and technique matter. The prescribing guidance does not rank one site above another, that decision is yours, guided by comfort and practicality. Some people find the abdomen easiest to reach; others prefer the thigh, particularly if they are self-injecting while seated. Our guide to Mounjaro injection sites goes into more detail on what makes each location practical for different people, including the upper arm, which is often the least convenient for solo use because reaching it cleanly can be awkward without a mirror or another person.

One practical point worth knowing: Mounjaro should not be injected into the same small area of skin repeatedly. Within whichever region you choose, move the actual needle entry point by at least a couple of centimetres from the previous week's spot. That small change makes a real difference over months of weekly injections.

Why site rotation matters, and what happens if you skip it

Repeated injections into the same patch of skin can cause lipohypertrophy: a build-up of fibrous, fatty tissue that feels firm or lumpy under the fingers. Beyond being uncomfortable, it matters clinically because absorption from lipohypertrophic tissue is slower and less predictable. Research in insulin-using patients with diabetes (a much longer-studied injection population) has consistently shown that injecting into hardened sites contributes to variable drug levels. The principle applies equally to subcutaneous GLP-1 medicines.

A simple rotation pattern reduces this risk substantially. Many people work clockwise around the abdomen (upper right, upper left, lower left, lower right) before moving to the thigh or arm, then back again. Others alternate the site category each week: abdomen one week, thigh the next. Either approach works provided you are genuinely moving the needle entry point and not just nudging a centimetre within the same hardened area.

If you notice a lump, tenderness or visible change at any site, stop using that area and flag it to your prescriber. It is also worth checking for any skin reaction at the jab site after each injection, mild redness that settles within a day or two is common, but anything that worsens or persists needs clinical attention. The full guide to Mounjaro injection site reactions covers those signs in more detail.

Practical technique points backed by the SmPC

Beyond location and rotation, a few technique details reduce discomfort and support consistent absorption. The pen should come out of the fridge roughly 30 minutes before use, injecting cold medicine is more likely to sting. Check your Patient Information Leaflet for the exact room-temperature storage window; the SmPC gives a specific timeframe that governs how long a pen can safely sit out of refrigeration, and that window is stricter than many people assume.

Clean the chosen spot with an alcohol swab and let it dry fully before pressing the pen against the skin. The KwikPen is held at a 90-degree angle and does not require pinching the skin for most adults, the needle length is designed for standard subcutaneous tissue depth. Press the pen firmly until the orange cap is flush with the skin, hold for at least ten seconds after you hear the click, then check the yellow indicator in the window shows that the dose has been delivered.

Keeping the same weekly injection day helps maintain the rhythm many people find useful, a habit some of our patients build around a low-key moment like a quiet evening at home. If you miss a day, the SmPC guidance on what to do is specific; that decision belongs with your prescriber and the Patient Information Leaflet, not a general article. For more on the practicalities of starting Mounjaro, the Mounjaro injection guide walks through first-use steps.

Eligibility, access and what a prescriber reviews

Mounjaro is licensed in the UK for weight management in adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance. A BMI figure alone does not settle the question, the prescriber reviews your medical history, current medicines and overall picture before deciding whether tirzepatide is appropriate for you.

If you are using oral contraceptives, the NHS advises adding a non-oral contraceptive method for the first four weeks of Mounjaro treatment and for four weeks after each dose increase, because the medicine's effect on gastric emptying can reduce pill absorption. The NHS England weight management injections page covers this and other safety considerations, including advice for people due to have surgery. Anyone with a history of pancreatitis, medullary thyroid cancer or multiple endocrine neoplasia type 2 should discuss this with a clinician before starting.

Mounjaro is a prescription-only medicine; it cannot legally be supplied without a valid prescription from a clinician who has assessed you. For broader background on tirzepatide (how it works as a dual GIP and GLP-1 receptor agonist, what the trial results showed) the tirzepatide overview is a good place to start, and the Mounjaro information page covers the UK licence in full. If you are looking at what private treatment involves, the Mounjaro cost guide sets out the landscape honestly, including what a legitimate price should include.